Immunopharmacology of anti-lymphocyte antibody therapies in pediatric hematopoietic stem cell transplantation: redefining old agents with new insights
Abstract
An allogeneic stem cell transplantation is a treatment in which a patient receives healthy blood stem cells from a donor. This procedure can be life-saving for children with serious blood disorders, such as leukemia or inherited blood diseases. However, it is also an intensive treatment with significant risks, including infections, graft-versus-host disease (a reaction in which donor cells attack the patient’s body), and relapse of the original disease.
To reduce these risks, patients receive medications before transplantation that temporarily suppress the immune system. Two commonly used drugs are ATG and ATLG. Although these medicines have been used for many years, it is not yet fully understood how they behave in children’s bodies, how quickly they are broken down, and how they affect recovery of the immune system after transplantation.
This thesis investigates how ATG and ATLG act in the body and how they influence immune recovery following transplantation. Blood samples from pediatric patients were analyzed, and pharmacokinetic models were used to determine how much of the drug remains in the body and how long its effects last. The recovery of different immune cells was also studied. The findings help doctors tailor dosing more precisely to each individual patient. By optimizing dosing strategies, the treatment can potentially become safer and improve the chances of a successful transplant outcome
